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Editorial

Improving the Quality of Care in
Children with Juvenile Idiopathic
Arthritis: A Step in the Right
Direction
Juvenile idiopathic arthritis (JIA) is heterogeneous in both its
clinical presentation and etiology1,2. JIA can result in permanent physical disability due to joint damage, while additional
morbidity can be related to its treatment and to effects on
growth and development. Children with inadequately treated
or recalcitrant JIA may have chronic pain, mood disturbances,
and difficulty with peer relationships, school performance,
and attainment of educational and vocational goals3,4,5,6,7,8.
Improved health related quality of life (HRQOL) and physical function are increasingly recognized as key treatment
goals because of the influence of this illness on all aspects of
a child’s life9. Accurate evaluation of this multidimensional
and heterogeneous disease is challenging, but crucial to
improve the quality of care and outcomes in JIA.
Over the last decade there has been an increasing commitment to the assessment and improvement of quality of
care following the report of The Institute of Medicine (IOM)
Committee on Quality of Healthcare in America, “To Err is
Human”10. The American College of Rheumatology (ACR)
and American Board of Pediatrics have charged Pediatric
Rheumatology with developing quality measures (QM) for
JIA. The initial work of this group included use of an online
Delphi survey technique with participation from physicians,
advanced practice nurses, and parents of children with JIA
for the selection process of QM. In 2008, preliminary QM
were published11. A nominal group technique was used to
reach consensus on the proposed set of QM for the process
of care. These include 4 broad domains: disease control,
safety monitoring, access and relationship (patient/family
satisfaction with healthcare)12. Within several of the QM,
the use of validated, reliable, age-appropriate tools for
measurement of pain, HRQOL, functional ability, self-efficacy, and patient/ parent satisfaction is proposed. A collaborative network, “Pediatric Rheumatology Care and
Outcomes Improvement Network (PR-COIN),” has recently been established to develop and evaluate specific disease
management strategies to improve the care of children with
JIA and to determine how best to incorporate these strategies into clinical practice.

In this issue of The Journal, Filocamo, et al describe the
Juvenile Arthritis Multidimensional Assessment Report
(JAMAR), an instrument for assessment of children with
JIA for use in standard clinical care13. The authors proposed
that this report may help enhance the quality of care of children with JIA by addressing “efficiency” and “efficacy,”
two of the quality domains of the “STEEEP” acronym outlined by the IOM (safe, timely, effective, efficient, equitable, patient-centered)14. One of the novel aspects of this
tool is the inclusion of patient-reported outcomes (PRO), in
a single tool including morning stiffness, medication side
effects, self-report of articular symptoms, and patient satisfaction rating13. The inclusion of PRO is important to
improve quality of care as these are part of the “patient-centered care” domain of quality outlined by the IOM.
Patient-specific indices offer the advantage of identifying salient issues for each patient and are more likely to
focus medical attention on the relevant issues; however,
they also present unique challenges to ensure the item/measure is reliable, valid, and provides useful information.
Without standardization of the items, the response scales do
not have the same meaning for each patient. This can make
it difficult to understand the numeric meaning of a score.
Second, using the data beyond intraindividual comparison
is problematic15. Further studies are needed to improve our
understanding of how to interpret the numeric scores of
patient-specific indices at both the individual and group
level.
The JAMAR contains two measurement tools, the
Juvenile Arthritis Functionality Scale (JAFS)16 and the
Pediatric Rheumatology Quality of Life Scale17, which
were developed only recently. For both tools, initial validation studies have been reported. Although research on quality of care in pediatric rheumatology is in its infancy, there
has been a longstanding focus on the measurement and
reporting of disease outcome, HRQOL, and functional outcome in JIA. There are many tools available to measure
clinical response (i.e., ACR Pediatric 3018), functional status (i.e., CHAQ19), and quality of life (PedsQLTM20, Child
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Health Questionnaire21, JAQQ22). In addition, several of
these instruments have been validated and are more widely
used both in clinical and research settings. It would seem
rational to use these existing tools both in clinical care and
research to allow for comparison between patient groups.
The potential use of a multidimensional report as a surrogate for a clinical encounter is intriguing. It is interesting
to consider how we assess our individual patient’s status and
the factors that guide our management decisions. Studies
comparing the decision-making process after a clinical
encounter versus using the results of a multidimensional
report, such as the JAMAR, would be of interest.
In summary, JIA is a heterogeneous and multidimensional disease. Improving the process of quality care delivery is
a topical issue. The development of the JAMAR importantly illustrates the breadth and potential content in a multidimensional report. Future work should be focused on refining and validating the existing measures used in JIA both in
clinical practice and in the research setting. Particular attention needs to be focused on interpreting scores/summary
scales for PRO. An international consensus on disease activity measures, functional assessment, assessment of
HRQOL, and PRO is key to advancing work in this area. In
order to evaluate the QM for the process of care, universal
agreement on measures to be used will facilitate implementation of QM into routine clinical practice for clinicians. The
aim should be to minimize duplication of work and focus
on implementation of QM to improve the process of
care, then to evaluate these tools and refine them in the
plan-do-study-act rapid cycles of improvement23.
ROBERTA BERARD, MD, MSc, FRCPC,
Assistant Professor of Pediatrics,
University of Western Ontario,
London, Ontario;

RONALD M. LAXER, MDCM, FRCPC,
Division of Rheumatology,
The Hospital for Sick Children,
Professor of Paediatrics and Medicine,
University of Toronto,
Toronto, Ontario, Canada
Address correspondence to Dr. Laxer. E-mail: ronald.laxer@sickkids.ca

REFERENCES
1. Ravelli A, Martini A. Juvenile idiopathic arthritis. Lancet
2007;369:767-78.
2. Martini A. Lovell DJ. Juvenile idiopathic arthritis: state of the art
and future perspectives. Ann Rheum Dis 2010:69:1260-3.
3. Packham JC, Hall MA. Long-term follow-up of 246 adults with
juvenile idiopathic arthritis: education and employment.
Rheumatology 2002;41:1436-9.
4. Packham JC, Hall MA. Long-term follow-up of 246 adults with
juvenile idiopathic arthritis: functional outcome. Rheumatology
2002;41:1428-35.
5. Packham JC, Hall MA, Pimm TJ. Long-term follow-up of 246
adults with juvenile idiopathic arthritis: predictive factors for mood
and pain. Rheumatology 2002;41:1444-9.

6. Foster HE, Marshall N, Myers A, Dunkley P, Griffiths ID. Outcome
in adults with juvenile idiopathic arthritis: a quality of life study.
Arthritis Rheum 2003;48:767-75.
7. Packham JC, Hall MC. Long-term follow-up of 246 adults with
juvenile idiopathic arthritis: social function, relationships and
sexual activity. Rheumatology 2002;41:1440-3.
8. Minden K, Niewerth M, Listing J, Biedermann T, Bollow M,
Schöntube M, et al. Long-term outcome in patients with juvenile
idiopathic arthritis. Arthritis Rheum 2002;46:2392-401.
9. Brunner HI, Giannini EH. Health-related quality of life in children
with rheumatic diseases. Current Opin Rheumatol 2003;15:602-12.
10. Kohn LT, Corrigan JM, Donaldson MS, editors. To err is human.
Building a safer health system. Committee on Quality of Health
Care in America. Washington: Institute of Medicine; National
Academy Press; 1999.
11. Passo MH, Taylor J. Quality improvement in pediatric
rheumatology: what do we need to do? Curr Opin Rheumatol
2008;20:625-30.
12. Lovell DJ, Passo MH, Beukelman T, Bowyer SL, Gottlieb BS,
Henrickson M, et al. Measuring process of arthritis care. A
proposed set of quality measures for the process of care in juvenile
idiopathic arthritis. Arthritis Care Res 2011;63:10-6.
13. Filocamo G, Consolaro A, Schiappapietra B, Dalprà S, Lattanzi B,
Magni-Manzoni S, et al. A new approach to clinical care of juvenile
idiopathic arthritis: the Juvenile Arthritis Multidimensional
Assessment Report. J Rheumatol 2011;38:938-53.
14. Institute of Medicine (US). Committee on Quality of Healthcare in
America. Netlibrary Inc. Crossing the quality chasm: a new health
system for the 21st century. Washington, DC: Institute of Medicine:
2001.
15. Jolles BM, Buchbinder R, Beaton DE. A study compared nine
patient-specific indices for musculoskeletal disorders. J Clin
Epidemiol 2005;58:791-801.
16. Filocamo G, Sztajnbok F, Cespedes-Cruz A, Magni-Manzoni S,
Pistorio A, Viola S, et al. Development and validation of a new
short and simple measure of physical function for juvenile
idiopathic arthritis. Arthritis Rheum 2007;57:913-20.
17. Filocamo G, Schiappapietra B, Bertamino M, Pistorio A, Ruperto
N, Magni-Manzoni S, et al. A new short and simple health-related
quality of life measurement for paediatric rheumatic diseases:
initial validation in juvenile idiopathic arthritis. Rheumatology
2010;49:1272-80.
18. Giannini EH, Ruperto N, Ravelli A, Lovell DJ, Felson DT, Martini
A. Preliminary definition of improvement in juvenile arthritis.
Arthritis Rheum 1997;40:1202-9.
19. Singh G, Athreya BH, Fries JF, Goldsmith DP. Measurement of
health status in children with juvenile rheumatoid arthritis. Arthritis
Rheum 1994;37:1761-9.
20. Varni JW, Seid M, Smith Knight T, Burwinkle T, Brown J, Szer IS.
The PedsQL in pediatric rheumatology: reliability, validity, and
responsiveness of the Pediatric Quality of Life Inventory Generic
Core Scales and Rheumatology Module. Arthritis Rheum
2002;46:714-25.
21. Landgraf JM, Abetz L, Ware JE. The CHQ user’s manual. Boston:
The Health Institute, New England Medical Center; 1996.
22. Duffy CM, Arsenault L, Duffy KN, Paquin JD, Strawczynski H.
The Juvenile Arthritis Quality of Life Questionnaire —
development of a new responsive index for juvenile rheumatoid
arthritis and juvenile spondyloarthritides. J Rheumatol
1997;24:738-46.
23. Langley GJ, Nolan KM, Norman CL, Provost LP, Nolan TW. The
improvement guide: A practical approach to enhancing
organizational performance. 2nd ed. San Francisco: Jossey-Bass
Business & Management Series; 2009.
J Rheumatol 2011;38:789-90; doi:10.3899/jrheum.110047

Personal non-commercial use only. The Journal of Rheumatology Copyright © 2011. All rights reserved.
790

The Journal of Rheumatology 2011; 38:5; doi:10.3899/jrheum.110047

Downloaded on August 8, 2022 from www.jrheum.org

